Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas/Cardiome Anticipate Oct. 19 Vernakalant User Fee Date

This article was originally published in The Pink Sheet Daily

Executive Summary

Astellas’ resubmission of the atrial fibrillation agent’s NDA triggers a $10 million milestone payment to Cardiome.

You may also be interested in...



Cardiome Reports Positive Oral Vernakalant Data; Says Company Sale Is Possible

Canadian firm retains Merrill Lynch to advise on merger and acquisition strategies the same day it reports positive data.

Cardiome Reports Positive Oral Vernakalant Data; Says Company Sale Is Possible

Canadian firm retains Merrill Lynch to advise on merger and acquisition strategies the same day it reports positive data.

FDA Advisory Committee Meeting Planned To Review Atrial Fibrillation Drugs

Safety and efficacy of Cardiome/Astellas’ vernakalant and Solvay’s tedisamil will be debated during the Dec. 11-12 meeting, according to Cardiome.

Related Content

Topics

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel